HBV genotype B is associated with better response to interferon therapy in HBeAg(+) chronic hepatitis than genotype C

Hepatology

Volumn 36, Issue 6, 2002, Pages 1425-1430

  Wai, Chun Tao ^a   Chu, Chi Jen ^a   Hussain, Munira ^a   Lok, Anna S F ^a,b  

^a UNIVERSITY OF MICHIGAN   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA INTERFERON; HEPATITIS B(E) ANTIGEN; PREDNISONE; RECOMBINANT ALPHA2B INTERFERON; VIRUS DNA;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIVIRAL ACTIVITY; ARTICLE; CHRONIC HEPATITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; GENOTYPE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNE RESPONSE; LIVER BIOPSY; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROMOTER REGION; RANDOMIZED CONTROLLED TRIAL; RETROSPECTIVE STUDY; SEROCONVERSION; VIRUS CORE; VIRUS MUTATION; VIRUS STRAIN;

EID: 0036896130     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1053/jhep.2002.37139     Document Type: Article

References (25)

1. Lok AS, Heathcote EJ, Hoofnagle JH. Management of hepatitis B: 2000 - Summary of a workshop. Gastroenterology 2001;120:1828-1853.
2. Brook MG, Karayiannis P, Thomas HC. Which patients with chronic hepatitis B virus infection will respond to alpha-interferon therapy? Hepatology 1989;10:761-763.
3. Perrillo RP, Schiff ER, Davis GL, Bodenheimer HC Jr, Lindsay K, Payne J, Dienstag JL, et al. A randomized, controlled trial of interferon alfa-2b alone and after prednisolone withdrawal for the treatment of chronic hepatitis B. N Engl J Med 1990;323:295-301.
4. Perrillo RP, Lai CL, Liaw YF, Dienstag JL, Schiff ER, Schalm SW, Heathcote EJ, et al. Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B. Hepatology 2002;36:186-194.
5. Stuyver L, De Gendt S, Van Geyt C, Zoulim F, Fried M, Schinazi RF, Rossau R. A new genotype of hepatitis B virus: Complete genome and phylogenetic relatedness. J Gen Virol 2000;81:67-74.
6. Chu CJ, Lok AS. Clinical significance of hepatitis B virus genotypes. Hepatology 2002;35:1274-1276.
7. Erhardt A, Heineke U, Blondin D, Gerlich WH, Adams O, Heintges T, Niederau C, et al. Mutations of the core promoter and response to interferon treatment in chronic replicative hepatitis B. Hepatology 2000;31:716-725.
8. Kao JH, Wu NH, Chen PJ, Lai MY, Chen DS. Hepatitis B genotypes and the response to interferon therapy. J Hepatol 2000;33:998-1002.
9. Hunt CM, McGill JM, Allen MI, Condreay DL. Clinical relevance of hepatitis B viral mutations. Hepatology 2000;31:1034-1044.
10. Chan HL, Hussain M, Lok AS. Different hepatitis B virus genotypes are associated with different mutations in the core promoter and precore regions during hepatitis B e antigen seroconversion. Hepatology 1999;29:976-984.
11. Lok AS, Akarca US, Greene S. Predictive value ofprecore hepatitis B virus mutations in spontaneous and interferon-induced hepatitis B e antigen clearance. Hepatology 1995;21:19-24.
12. Brunetto MR, Giarin M, Saracco G, Oliveri F, Calvo P, Capra G, Randone A, et al. Hepatitis B virus unable to secrete e antigen and response to interferon in chronic hepatitis B. Gastroenterology 1993;105:845-850.
13. Schepis F, Verucchi G, Pollicino T, Attard L, Brancatelli S, Longo G, Raimondo G. Outcome of liver disease and response to interferon treatment are not influenced by hepatitis B virus core gene variability in children with chronic type B hepatitis. J Hepatol 1998;26:765-770.
14. Zhang X, Hian Y, Lu Z, Gao J, Luo Z, Zhang D. Effect of multiple mutations in the core promoter and pre-core/core region of hepatitis B virus genome on the response to interferon in e antigen-positive chronic hepatitis B. J Gastroenterol Hepatol 2001;16:393-398.
15. Hannoun C, Horal P, Krogsgaard K, Lindh M. Mutations in the X region and core promoter are rare and have little impact on response to interferon therapy for chronic hepatitis B. J Med Virol 2002;66:171-178.
16. Zollner B, Petersen J, Schafer P, Schroter M, Laufs R, Sterneck M, Feucht HH. Subtype-dependent response of hepatitis B virus during the early phase of lamivudine treatment. Clin Infect Dis 2002;34:1273-1277.
17. Kao JH, Liu CJ, Chen DS. Hepatitis B viral genotypes and lamivudine resistance [Letter]. J Hepatol 2002;36:303-305.
18. Westland C, Delaney W, Ynag HL, Fry J, Brosgart C, Gibbs C, Miller M, et al. Distribution and clinical response of HBV genotypes in phase III studies of adefovir dipivoxil [Abstract]. J Hepatol 2002;36(Supp 1):105.
19. Lok A, Wu PC, Lai CL, Lau JY, Leung EK, Wong LS, Ma OC, et al. A controlled trial of interferon with or without prednisone priming for chronic hepatitis B. Gastroenterology 1992;102:2091-2097.
20. Chu CJ, Hussain M, Lok AS. Hepatitis B virus genotype B is associated with earlier HBeAg seroconversion compared with hepatitis B virus genotype C. Gastroenterology 2002;122:1756-1762.
21. Chu CJ, Hussain M, Lok A. Concordance between line probe assay and direct sequencing for determination of HBV genotype [Abstract]. Hepatology 2001;34:616A.
22. Chu CJ, Han SH, Perrillo RP, Keeffe E, Min AD, Carey W, Soldevila-Pico C, et al. Prevalence of HBV molecular epidemiology of HBV infection in the United States [Abstract]. Hepatology 2001;34:617A.
23. Pas SD, de Man RA, Fries E, Osterhaus AD, Niesters HG. The dynamics of mutations in the YMDD motif of the hepatitis B virus polymerase gene during and after lamivudine treatment as determined by reverse hybridisation. J Clin Virol 2002;25:63-71.
24. Lok ASF, McMahon BJ. Chronic hepatitis B. Hepatology 2001;34:1225-1241.
25. Core working party for Asia-Pacific consensus on hepatitis B and C. Consensus statements on the prevention and management of hepatitis B and hepatitis C in the Asia-Pacific region. J Gastroenterol Hepatol 2000;15:825-841.